Amgen: Breast Neoplasms trials

The registry lists 19 Breast Neoplasms studies with Amgen as lead sponsor. 0 are open to participants now and 8 have results posted.

Phase 1 3Phase 2 10Phase 3 6(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver MetastasesCompletedNCT03256344Phase 1Results posted
• Efficacy and Safety Study of ABP 980 Compared With Trastuzumab in Women With HER2-positive Early Breast CancerCompletedNCT01901146Phase 3Results posted
• Effect of Patient Education on Reported Bone Pain in Breast Cancer Patients Receiving Chemotherapy and PegfilgrastimCompletedNCT01752907Phase 2Results posted
• NOLAN: Naproxen or Loratadine and NeulastaCompletedNCT01712009Phase 2Results posted
• Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)TerminatedNCT01077154Phase 3Results posted
• Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor TherapyCompletedNCT00556374Phase 3Results posted
• Denosumab (AMG 162) in Bisphosphonate Naive Metastatic Breast CancerCompletedNCT00091832Phase 2Results posted
• AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast CancerCompletedNCT00089661Phase 3Results posted
• Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast CancerActive, not recruitingNCT03937154Phase 3
• Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast CancerCompletedNCT00807859Phase 1
• Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer PatientsCompletedNCT00511459Phase 2
• A Study of AMG 706 or Bevacizumab, in Combination With Paclitaxel Chemotherapy, as Treatment for Breast CancerTerminatedNCT00356681Phase 2
• Phase1b to Evaluate Safety of AMG706 in Combination With Paclitaxel or Docetaxel for Breast CancerCompletedNCT00322400Phase 1
• ACCELERATE: Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Pegfilgrastim and Darbepoetin Alfa Support for the Treatment of Women With Breast CancerCompletedNCT00261313Phase 2
• A Study of Cyclophosphamide/Methotrexate/5-Fluorouracil (CMF) With Pegfilgrastim in Subjects With Breast CancerCompletedNCT00124111Phase 2
• Treatment for Patients Suffering From Anemia Due to ChemotherapyCompletedNCT00120692Phase 2
• Treatment for Elderly Patients With High Risk Breast CancerCompletedNCT00117910Phase 3
• Same Day Dosing of Pegfilgrastim in Breast Cancer Patients Undergoing Chemotherapy (TAC)CompletedNCT00115414Phase 2
• Chemotherapy Related Anemia in Patients With Non-Myeloid MalignanciesCompletedNCT00036023Phase 2